Omeprazole pharmacokinetics in adults
Pro Research Analysisby 
Searched over 200M research papers
Omeprazole Pharmacokinetics in Healthy Adults: Absorption, Distribution, and Clearance
In healthy adults, omeprazole is typically administered orally and follows a one-compartment pharmacokinetic model with zero-order or transit absorption and linear elimination. The mean oral clearance (CL/F) is about 0.62 L/h/kg, and the apparent volume of distribution (Vss/F) is approximately 0.76 L/kg. There is a notable lag time in absorption, averaging around 0.62 hours in adults, which is longer than in pediatric populations. The drug’s bioavailability increases with repeated dosing, likely due to reduced gastric acidity enhancing absorption of this acid-labile compound. After five days of dosing, the relative bioavailability can increase two- to threefold compared to the first dose, and the maximal effect on gastric pH is observed after several days of treatment. Omeprazole significantly raises intragastric pH, with a mean pH of about 4.3 after a 40 mg dose in non-obese adults, and maintains a high level of acid suppression throughout the day Marier2004Prichard1985Pippa2024.
Impact of Obesity and Bariatric Surgery on Omeprazole Pharmacokinetics
Obesity alters omeprazole pharmacokinetics by reducing drug clearance, which leads to higher systemic exposure. This effect is attributed to decreased activity of hepatic CYP2C19 and CYP3A4 enzymes in obese individuals. As a result, obese patients may require lower doses of omeprazole for long-term therapy to avoid excessive drug exposure and potential adverse effects. After bariatric surgery, such as Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy, the absorption rate of omeprazole increases (shorter Tmax and higher Cmax), but overall drug exposure (AUC) and clearance remain unchanged. Enzyme activity is restored post-surgery, and a standard 20 mg daily dose is generally sufficient for symptom relief in the short term after surgery Chen2022Pippa2024Chen2022.
Influence of CYP2C19 Genotype on Omeprazole Metabolism
Omeprazole is primarily metabolized by the CYP2C19 enzyme. Genetic variations in CYP2C19 significantly affect omeprazole clearance and systemic exposure. Poor metabolizers (PMs) have higher omeprazole plasma concentrations and lower levels of its primary metabolite, 5-hydroxyomeprazole, compared to extensive (EM) and intermediate metabolizers (IMs). This pattern is consistent in both elderly and younger adults, though the differences between genotype groups are less pronounced in the elderly. The CYP2C19 genotype remains a key determinant of omeprazole pharmacokinetics across different adult populations, including those with obesity or after bariatric surgery Chen2022Na2021Chen2022.
Drug-Drug Interactions Affecting Omeprazole Pharmacokinetics
Omeprazole’s pharmacokinetics can be influenced by co-administered drugs that affect CYP2C19 activity. For example, elagolix, a weak CYP2C19 inhibitor, increases omeprazole exposure by 1.8- to 2.5-fold in EM and IM subjects, but decreases exposure by 40% in PMs. Omeprazole itself can also affect the pharmacokinetics of other drugs, such as ibrutinib and revexepride, but these interactions are generally not clinically significant in terms of overall drug exposure (AUC), though they may affect peak concentrations (Cmax) and time to maximum concentration (Tmax) Nader2022Jong2016Pierce2015.
Modeling and Predicting Omeprazole Pharmacokinetics
Physiologically based pharmacokinetic (PBPK) models have been developed to predict omeprazole exposure in adults and special populations. These models incorporate factors such as age, obesity, enzyme activity, and drug-drug interactions, and can accurately simulate plasma concentrations and pharmacodynamic effects (e.g., changes in intragastric pH). PBPK modeling is a valuable tool for optimizing dosing recommendations and understanding variability in omeprazole pharmacokinetics among adults Pippa2024Soliman2025.
Conclusion
Omeprazole pharmacokinetics in adults are influenced by body weight, genetic variation in CYP2C19, and co-administered drugs. Obesity reduces clearance and increases exposure, while bariatric surgery increases absorption rate but not overall exposure. CYP2C19 genotype is a major determinant of metabolism, and drug-drug interactions can further modify omeprazole levels. PBPK models provide a comprehensive framework for predicting these effects and guiding individualized dosing in adults.
Sources and full results
Most relevant research papers on this topic